Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 11/20 | 0.42 |
| ▸ | CCNH | P51946 | 10/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.42 |
| ▸ | CDK2 | P24941 | 10/20 | 0.38 |
| ▸ | CDK9 | P50750 | 8/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23351991 | 0.91 | CDK7 (0.44) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL21482003 | 0.90 | CDK7 (0.40) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23352106 | 0.90 | CDK7 (0.44) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23352002 | 0.90 | CDK7 (0.43) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL21481485 | 0.90 | CDK7 (0.43) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23352020 | 0.90 | CDK7 (0.43) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23351998 | 0.89 | CDK7 (0.44) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23352107 | 0.88 | CDK2 (0.48) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL26340881 | 0.88 | CDK7 (0.42) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL23351989 | 0.88 | CDK2 (0.48) | CDK7CCNHMNAT1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| WO-2023175173-A1 | CDK7 INHIBITORS FOR ANTIVIRAL TREATMENT | QURIENT CO., LTD. (KR) | 2023-09-21 | — | — | WO | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | CDK7 10/4885CCNH 56/4885MNAT1 94/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | CDK7 159/4885CCNH 1109/4885MNAT1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.